US FDA and EMA accept applications for Roche?s OCREVUS (ocrelizumab) shorter 2-hour infusion time
- Reduces infusion time to 2 hours from the current 3.5 hours for patients with relapsing or primary progressive multiple sclerosis, if approved
- Applications are based on data from the randomised, double-blind ENSEMBLE PLUS study, showing consistent safety to the currently approved OCREVUS dosing regimen
Attachment